// App-Quantinova.ai

OT3-17-03 : Impact of the Oncotype DX breast cancer assay on treatment decisions in a UK population of patients with oestrogen receptor positive early breast cancer with 1-3 lymph nodes positive who are candidates for chemotherapy, but for whom the benefits are uncertain - Interim results

Researchers

Presenter

  • Daniel Thomas

Principal Investigators

  • Caroline Archer

  • Anne Rigg

  • Tamas Hickish

  • Jo Dent

  • Laura Pettit

  • Marianne Dillon

  • Christy Goldsmith

  • Mark Verrill

  • Ludger Barthelmes

  • Saira Khawaja

  • Yousef Sharaiha

  • Mark Davies

  • Fawaz Arikat

  • Sahail Khan

  • Asma Munir

  • Anita Huws

  • Simon DavidHenry Holt

Medical Centers

  • Prince Philip Hospital, Llanelli, United Kingdom

  • Queen Alexandra Hospital, Portsmouth, United Kingdom

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Royal Bournemouth Hospital, Bournemouth, United Kingdom

  • Calderdale and Huddersfield Royal Infirmary, Huddersfield, United Kingdom

  • Royal Shrewsbury Hospital, Shrewsbury, United Kingdom

  • Singleton Hospital, Swansea, United Kingdom

  • Kings College London, London, United Kingdom

  • Royal Victoria Infirmary, Newcastle, United Kingdom

  • North Cumbria University Hospital NHS Trust, Cumbria, United Kingdom

  • Oncology, Withybush General Hospital, Haverfordwest, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved